Menard Financial Group LLC Buys 24 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Menard Financial Group LLC raised its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,014 shares of the biotechnology company’s stock after acquiring an additional 24 shares during the period. Axon Enterprise comprises approximately 0.8% of Menard Financial Group LLC’s investment portfolio, making the stock its 29th largest holding. Menard Financial Group LLC’s holdings in Axon Enterprise were worth $1,204,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Westfield Capital Management Co. LP lifted its holdings in Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after acquiring an additional 127,769 shares during the period. Champlain Investment Partners LLC boosted its holdings in shares of Axon Enterprise by 13.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after buying an additional 83,265 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Axon Enterprise by 1.6% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 561,263 shares of the biotechnology company’s stock valued at $224,281,000 after buying an additional 9,090 shares during the period. 1832 Asset Management L.P. raised its position in Axon Enterprise by 44.0% in the second quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after acquiring an additional 114,800 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in Axon Enterprise by 13.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock valued at $108,496,000 after acquiring an additional 45,049 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Axon Enterprise

In other news, CEO Patrick W. Smith sold 47,314 shares of Axon Enterprise stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $400.07, for a total transaction of $18,928,911.98. Following the sale, the chief executive officer now owns 2,983,802 shares of the company’s stock, valued at approximately $1,193,729,666.14. The trade was a 1.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeri Williams sold 110 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $400.00, for a total transaction of $44,000.00. Following the completion of the transaction, the director now directly owns 1,934 shares of the company’s stock, valued at approximately $773,600. The trade was a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 135,256 shares of company stock worth $61,043,370. 5.70% of the stock is currently owned by insiders.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $669.87 on Wednesday. The company has a market capitalization of $51.08 billion, a P/E ratio of 173.09, a P/E/G ratio of 14.00 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a 52-week low of $229.02 and a 52-week high of $675.47. The company has a fifty day moving average of $498.62 and a 200-day moving average of $385.31.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $500.00 to $700.00 in a report on Tuesday. JMP Securities increased their price target on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 31st. Craig Hallum boosted their price objective on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Northland Securities increased their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Finally, The Goldman Sachs Group boosted their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Axon Enterprise presently has an average rating of “Moderate Buy” and an average target price of $460.33.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.